starting from ~120k my goal is to hit 1M by 2028 latest. until then I will invest aggressively and take considerable risk. plan is to ~2x my portfolio each year
The Scorpion report on $ABVX has an odd shape:
Lots of angles, none decisive —
lipophilic "carcinogen", UV phototoxicity, monkey tox, a retracted MoA paper, China sites, adjudication.
One by one, much of it is thin. High logP is a PK question, not proof of carcinogenicity. The ICH S10 UV threshold triggers more testing, not a verdict. Target organs in high-dose tox are routine. Approval rests on RCTs, not on a mechanism paper.
For the thesis to hold, the drug would have to be toxic, the trials manipulated and the effect weak, all at once, with the CRO, auditors, DSMB and regulators all missing it — That is very unlikely.
Compare the Madrigal whistleblower suit: one insider (ex-head of clinical development), one consistent story about one issue, liver safety data.
This reads like a thin core padded out to look heavier. Abivax still owes a detailed rebuttal.
Disclosure: long $ABVX
@unterhuber Es ist aber schon erstaunlich wenn er von einer „wir“ Erb-Schuld spricht die -wenn überhaupt- auf Vorfahren zurückgeht mit denen er nur sehr sehr entfernt verwandt ist…
It’s not only about the low % of North Americans, it’s mainly about the substantially lower effect sizes and responders in the North American population that deviates from the rest of the study participants. There are many explanations to this (ethnicity, severity of disease, response to prior therapies) that could explain it, but it is certainly something the FDA will ask too…
FDA is saying the trial was fraudulent: $CAPR. They rarely are this blunt.
"The correspondence identifies serious data integrity violations in the conduct of Study HOPE-3 that cannot be remediated post-hoc."
"Among the deficiencies identified in the CRL, is that serious clinical trial data integrity deficiencies identified in Study HOPE-3 render the study data unreliable and incapable of post hoc remediation."
Capricor and @MarbanLab at Cedars-Sinai are both frauds. Despicable.
@ScorpionFund You publish it to create a sell off and cover your shorts as you even admitted.
Don’t claim to have good intentions here if your thesis is so weak.
@Edyy55@TheLongInvest This narcissist turns angry when you call him out. He will blame you didn’t follow “his strategy” and other stuff, but never admit he gave false advice…
I wouldn’t touch $mdgl until this is resolved. The accusations are very concrete and even the missmanagement of potential safety issues are punishable.
Trust in safety is of upmost importance.
This is a fantastically stupid take on $MDGL.
Merck characterized Vioxx's launch in its 1999 annual report as: “Vioxx: Our biggest, fastest and best launch ever.”
How did that turn out?
The speed of a commercial launch says effectively nothing about latent toxicity.
I am out of $MDGL as of this morning. Maybe the whistleblower claim proves to be without merit. However, it should be taken extremely seriously until such time as $MDGL provides evidence for that.
Biography of the whistleblower below, btw.
Anyone attempting to claim the complaint is bullshit a priori has absolutely zero basis for doing so until more information comes out.
Lastly, if $IVA hits its Phase III on the heels of this, $MDGL will be pummeled. Whatever you think the fair value of $MDGL is, pure trading dynamics alone will drive it into the ground.
$ABVX There isn’t a BD team anywhere in Pharma that can’t read this chart and understand what’s coming for their IBD franchises if they lose out. Just reality.